Zimmer Biomet surprised this week with the announcement that CEO David Dvorak is immediately stepping down. So who will replace him? For now, the orthopedic device giant’s SVP and CFO Dan Florin will serve as interim CEO while the company’s board searches for a new permanent CEO. It is unclear whether Florin – who was VP and […]
Bill Hawkins on his time at Medtronic, Immucor and 25 years in the hot seat | DeviceTalks podcast
For nearly a quarter of a century, William “Bill” Hawkins sat in the corner office of medtech companies of all sizes, before stepping down from Immucor last year to become the Atlanta-based company’s lead director. Hawkins is best known for his 4 years as CEO of Medtronic, where he served in the corner office from […]
Bioventus taps ex-Medtronic CEO Hawkins for chairman | Personnel Moves
Bioventus said it tapped former Medtronic (NYSE:MDT) and Immucor (NSDQ:BLUD) chief Bill Hawkins to be its new chairman, replacing Dan LeMaitre. Hawkins, who’s slated to appear at the upcoming DeviceTalks event in Raleigh, N.C., had the corner office at Medtronic from 2007 until 2011, when he took the helm at Immucor, where is he lead director. […]
Ex-Biomet CEO Binder is Immucor’s new chief exec | Personnel Moves
Immucor said it named Jeffrey Binder, who led Biomet until its $13.34 billion merger with Zimmer (NYSE:ZMH), to be its new chairman, president & CEO. Binder replaces William Hawkins, the former Medtronic (NYSE:MDT) chief executive who took the reins at Immucor in 2011. Hawkins will assume the role of lead director on Immucor’s board, that company said. Immucor is […]
Bidding war for Carestream heats up | Wall Street Beat
At least 5 major private equity players are vying for medical device company Carestream Health, including Bain Capital, Carlyle Group and KKR & Co., according to Reuters.
Onex Corp. is hoping to unload Carestream, formed in the 2007 spinout of Eastman Kodak Co.’s healthcare business, for up to $3.5 billion, the news service reported.
Hologic sells Lifecodes to Immucor for $85M
Former Medtronic CEO nets $8M in comp package during 2012
Moody’s estimates med-tech tax impact
The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody’s Investor Services, according to a report by the ratings agency.
The tax will help slow EBIDTA growth rates for the med-tech sector to between 1% and 4% over the next year to 18 months, according to Moody’s, with organic growth rates of between 2% and 3% during that period.
Ex-Medtronic CEO Hawkins to chair new med-tech research center | Personnel Moves
Former Medtronic (NYSE:MDT) CEO Bill Hawkins will serve as the first chairman of a new private-public partnership aimed at improving development and testing of medical devices.
The partnership includes the Minnesota med-tech community, the FDA’s Center for Devices & Radiological Health and the University of Minnesota to establish a regulatory science center in the North Star State.
Thoratec taps ex-Medtronic CEO Hawkins for board | Personnel Moves
Stu Randle talks to MassDevice, Immucor taps Hawkins, FDA spurs innovation, Lasik docs, Covidien’s Thailand move, Medtronic in Puerto Rico, Med-tech starts overseas | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
